C-terminal residue optimization and fragment merging: Discovery of a potent peptide-hybrid inhibitor of dengue protease

Mira A.M. Behnam, Christoph Nitsche, Sérgio M. Vechi, Christian D. Klein*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

56 Citations (Scopus)

Abstract

Dengue virus protease is a promising target for the development of antiviral drugs. We describe here a two-step rational optimization that led to the discovery of the potent inhibitor 35 with nanomolar binding affinity at dengue protease serotype 2 (IC50 = 0.6 μM, Ki = 0.4 μM). First, a large number of natural and non-natural amino acids were screened at the C-terminal position of the previously reported, canonical peptide sequence (Cap-Arg-Lys-Nle-NH2). Compared to the reference compound 1 (Bz-Arg-Lys-Nle-NH2, IC50 = 13.3 μM), a 4-fold higher inhibitory potential was observed with the incorporation of a C-terminal phenylglycine (compound 9, IC50 = 3.3 μM). Second, we applied fragment merging of 9 with the previously reported thiazolidinedione peptide hybrid 33 (IC50 = 2.5 μM). This approach led to the fusion of two inhibitor-fragments with micromolar affinity into a 20-fold more potent, competitive inhibitor of dengue protease.

Original languageEnglish
Pages (from-to)1037-1042
Number of pages6
JournalACS Medicinal Chemistry Letters
Volume5
Issue number9
DOIs
Publication statusPublished - 11 Sept 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'C-terminal residue optimization and fragment merging: Discovery of a potent peptide-hybrid inhibitor of dengue protease'. Together they form a unique fingerprint.

Cite this